The transition from platform to product: Jean-Paul Kress on reshaping MorphoSys
CEO Jean-Paul Kress leads German biotech’s pivot away from its mAb legacy
Nearly four years into his role as CEO of MorphoSys, Jean-Paul Kress is in the midst of engineering a transition that nearly all platform companies face: from a technology and partnering model to an integrated commercial organization.
Perennial questions faced by platform companies are how much capital to allocate to continued technology innovation versus financing programs generated by the platform, and knowing when the tech may no longer be differentiated enough from competitors, warranting transition to a product-centered company. ...
BCIQ Company Profiles
BCIQ Target Profiles